Xortx reports annual & special meeting results

Calgary, alberta, july 22, 2022 (globe newswire) -- xortx therapeutics inc. ("xortx" or the “company”) (nasdaq: xrtx | tsxv: xrtx | frankfurt: anu), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the results of the company's 2022 annual and special meeting of shareholders held july 20, 2022 (the “meeting”). a total of 4,526,004 common shares of the company were voted at the meeting, representing approximately 35% of the total number of issued and outstanding shares. at the meeting, all resolutions passed close to unanimously. all seven director nominees, dr. allen davidoff, william farley, anthony giovinazzo, ian klassen, jacqueline le saux, raymond pratt and paul van damme, were elected as directors of the company. in addition, shareholders voted to re-appoint smythe llp as auditors of the company and also approved the company's 10% rolling stock option plan.
XRTX Ratings Summary
XRTX Quant Ranking